Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of “Moderate Buy” by Brokerages

Outlook Therapeutics, Inc. (NASDAQ:OTLK) has received a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $32.73.

A number of equities analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday, November 29th. Chardan Capital reiterated a “neutral” rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. Finally, BTIG Research cut their target price on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, November 29th.

Institutional Investors Weigh In On Outlook Therapeutics

Large investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in Outlook Therapeutics in the 2nd quarter valued at about $75,000. Christensen King & Associates Investment Services Inc. purchased a new position in Outlook Therapeutics in the third quarter valued at about $55,000. Barclays PLC grew its stake in Outlook Therapeutics by 677.4% during the 3rd quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after purchasing an additional 18,249 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Outlook Therapeutics by 55.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock worth $275,000 after purchasing an additional 18,287 shares during the last quarter. Finally, State Street Corp raised its position in shares of Outlook Therapeutics by 10.0% in the 3rd quarter. State Street Corp now owns 232,542 shares of the company’s stock valued at $1,242,000 after purchasing an additional 21,201 shares in the last quarter. 11.20% of the stock is owned by institutional investors and hedge funds.

Outlook Therapeutics Stock Performance

Outlook Therapeutics stock opened at $2.37 on Monday. Outlook Therapeutics has a 1 year low of $0.87 and a 1 year high of $12.85. The firm has a 50 day moving average price of $3.11 and a 200 day moving average price of $5.51. The company has a market cap of $59.03 million, a price-to-earnings ratio of -0.22 and a beta of 0.53.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings data on Friday, December 27th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.06. Sell-side analysts predict that Outlook Therapeutics will post -3.84 EPS for the current year.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.